ArticleJournal of thoracic disease2025

Neoadjuvant dual immuno-combination therapy with anti-LAG3 and anti-PD-1 antibodies is feasible and safe for resectable non-small cell lung cancer.

Naoki Furuya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.